New York Blade (09.28.01) - Friday, October 05, 2001
Lisa Keen

Hepatitis B, like HIV, often lies dormant for years and then relapses into life-threatening liver disease. Two studies this year suggested that such relapses might be associated with protease inhibitor combinations; a study last year linked relapse to discontinuing the nucleoside 3TC. Also like HIV, hepatitis B can be transmitted through bodily fluids during sex, making co- infection "relatively common," says the National Institute of Allergy and Infectious Diseases. Hepatitis B both weakens the patient and triggers replication of HIV.

To be put on the list for a liver, which is maintained by the United Network for Organ Sharing (UNOS), a patient must be evaluated by a hospital that performs liver transplants. Moving to the top of the list is reserved for patients with "sudden liver failure that leaves them with a life expectancy of fewer than seven days," according to UNOS policy, which is up for revision this year. It also suggests that a patient with HIV and without HIV symptoms "should not necessarily be excluded from candidacy for organ transplantation." UNOS requires HIV screening of all potential recipients. Since 1988, only 37 liver transplants have been performed on people with HIV. The 11 of those performed last year represented less than 1 percent of the 4,955 liver transplants carried out in 2000.

Activist Larry Kramer, who has AIDS and hepatitis and needs a liver transplant, described the many obstacles facing those needing the procedure. People seeking a transplant often affiliate themselves with hospitals in several cities, each of which typically requires a battery of expensive tests and may demand a deposit of up to $500,000. Kramer, who is on the list to receive a liver at the University of Pittsburgh Medical Center, described navigating the complex system as "like dealing in a foreign language and a foreign country."
011005
AD011873

Copyright © 2001 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.